http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-202115121-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0ae0f07170be484b5f269bee22bbeb13 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2020-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8a30e37a5913f9d631556043fa1b6df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8c20b3ca301ac8650eef2a44901b12c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6dc4d9e502b12b1120642250a57bc55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65c6f937cb2fab3b7eb475abdc8fa036 |
| publicationDate | 2021-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-202115121-A |
| titleOfInvention | Anti-pd-l1 antibodies and uses thereof |
| abstract | The present invention providesa PD-L1 immunosuppressant, specifically, a monoclonal antibody capable of targeting PD-L1, nucleotides or polynucleotide combinations and expression vectors or expression vector combinations encoding the antibodies. The present invention also provides a conjugate or pharmaceutical composition comprising the anti-PD-L1 antibody. The present invention further provides uses of the aforementioned nucleotides, polynucleotide combinations, expression vectors, expression vector combinationsencoding the anti-PD-L1 antibodies, conjugatesor pharmaceutical compositionsin the manufacture of a medicine for treating or preventing cancers. The anti-PD-L1 monoclonal antibodies provided by the present invention has good affinity with human PD-L1 and exhibits good specificity, and can compete with human PD-1 to bind to human PD-L1. The anti-PD-L1 monoclonal antibodies provided by the present invention shows a good tumor suppressing effect for non-small cell lung cancer and colorectal cancer in animal models. |
| priorityDate | 2019-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 64.